Biopharmaceutical CDMO Service Market (By Type: Cell and Gene Therapies, Antibodies, Vaccines, and Others; By Application: SMBs and Large Companies; By Region: North America, Europe, Asia-Pacific, and LAMEA) Industry Size, Share, Growth, Trends 2026 to 2035.
The global biopharmaceutical CDMO services market was valued at USD 31.49 billion in 2024 and is projected to reach approximately USD 108.81 billion by 2034, expanding at a CAGR of 13.20%, driven by rising biologics demand, outsourcing trends, and advanced manufacturing capabilities.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 31.49 Billion |
| Market Size in 2026 | USD 35.65 Billion |
| Market Size in 2032 | USD 75.01 Billion |
| Market Size by 2035 | USD 108.81 Billion |
| CAGR 2026 to 2035 | 13.20% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The biopharmaceutical CDMO service market is expanding due to the outsourcing of drug development and manufacturing by pharmaceutical and biotech companies. The need for cost-effective production and expanding biologics pipelines are important motivators. Growth is being boosted by the need for specialized knowledge. Strategic alliances between biopharmaceutical companies and CDMOs are accelerating market growth.
Significant growth prospects for CDMOs are presented by emerging small and mid-sized biotech firms looking for outsourcing partnerships. Expanding into cutting-edge treatments like gene therapy and medications based on mRNA can open lucrative contracts. Global reach and cost competitiveness can be enhanced in emerging economies through capacity expansion. Long term manufacturing agreements and strategic partnerships enhance market potential even more.
| Regions | Shares (%) |
| North America | 39% |
| Europe | 27% |
| Asia Pacific | 24% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Cell and Gene Therapies | 28% |
| Antibodies | 34% |
| Vaccines | 22% |
| Other | 16% |
| Segments | Shares (%) |
| SMBs | 46% |
| Large Companies | 54% |
Published by Ajit Bansod
